<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-109434</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">From scientific evidence to clinical practice: treatment regimens for macular edema secondary to retinal vein occlusion</dc:title>
<dc:description xml:lang="en">Retinal vein occlusion (RVO) is the second most common cause of retinal vascular disease after diabetic retinopathy. Despite the existence of several possible treatment options, none was entirely satisfactory and many patients suffered irreversible visual loss. As a result of the BRAVO, CRUISE and GENEVA trials, ranibizumab and the intravitreal biodegradable implants of dexamethasone has recently been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of RVO secondary edema. In this paper we begin by describing the current treatment options for RVO associated macular edema and continue with the description of the treatment regimen with ranibizumab(AU)</dc:description>
<dc:creator>Gómez-Ulla, F</dc:creator>
<dc:creator>Abraldes, M. J</dc:creator>
<dc:creator>Zapata, M. A</dc:creator>
<dc:creator>García-Arumí, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las oclusiones venosas de la retina (OVR) son la segunda causa más frecuente de enfermedad vascular de la retina después de la retinopatía diabética. A pesar de la existencia de varias opciones terapéuticas posibles, ninguna resultó del todo satisfactoria, y muchos pacientes sufrían una pérdida visual irreversible. Como resultado de los ensayos BRAVO,CRUISE y GENEVA, ranibizumab y los implantes intravítreos biodegradables de dexametasona han sido recientemente aprobados por la Food and Drug Administration en los Estados Unidos y por la Agencia Europea del Medicamento para el tratamiento del edema macular secundario a OVR. En este trabajo comenzamos describiendo las opciones actuales de tratamiento para el edema macular secundario a oclusión venosa retiniana y continuamos con la descripción de la pauta de tratamiento con ranibizumab(AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;87(supl.1): 54-62, dic. 2012. graf, ilus</dc:source>
<dc:identifier>ibc-109434</dc:identifier>
<dc:title xml:lang="es">De la evidencia científica a la práctica clínica: pautas de tratamiento del edema macular secundario a oclusión venosa retiniana</dc:title>
<dc:subject>^d22418^s22073</dc:subject>
<dc:subject>^d8204^s22066</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8204^s22045</dc:subject>
<dc:subject>^d53367^s22045</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d33150^s22045</dc:subject>
<dc:subject>^d19336^s22016</dc:subject>
<dc:subject>^d28131^s22054</dc:subject>
<dc:subject>^d28131^s29166</dc:subject>
<dc:subject>^d33150^s22066</dc:subject>
<dc:subject>^d28131^s22067</dc:subject>
<dc:subject>^d34460^s22073</dc:subject>
<dc:subject>^d19336^s22012</dc:subject>
<dc:subject>^d19336^s22067</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d3008^s22045</dc:subject>
<dc:subject>^d3008^s22066</dc:subject>
<dc:subject>^d28131^s22016</dc:subject>
<dc:subject>^d19336^s29166</dc:subject>
<dc:subject>^d19336^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
